CME‐1, a novel polysaccharide, suppresses iNOS expression in lipopolysaccharide‐stimulated macrophages through ceramide‐initiated protein phosphatase 2A activation

Abstract CME‐1, a novel water‐soluble polysaccharide purified from Ophiocordyceps sinensis mycelia, has anti‐oxidative, antithrombotic and antitumour properties. In this study, other major attributes of CME‐1, namely anti‐inflammatory and immunomodulatory properties, were investigated. Treating lipopolysaccharide (LPS)‐stimulated RAW 264.7 cells with CME‐1 concentration‐dependently suppressed nitric oxide formation and inducible nitric oxide synthase (iNOS) expression. In the CME‐1‐treated RAW 264.7 cells, LPS‐induced IκBα degradation and the phosphorylation of p65, Akt and mitogen‐activated protein kinases (MAPKs), including extracellular signal‐regulated kinase, c‐Jun N‐terminal kinase and p38, were reduced. Treatment with a protein phosphatase 2A (PP2A)‐specific inhibitor, significantly reversed the CME‐1‐suppressed iNOS expression; IκBα degradation; and p65, Akt and MAPK phosphorylation. PP2A activity up‐regulation and PP2A demethylation reduction were also observed in the cells. Moreover, CME‐1‐induced PP2A activation and its subsequent suppression of LPS‐activated RAW 264.7 cells were diminished by the inhibition of ceramide signals. LPS‐induced reactive oxygen species (ROS) and hydroxyl radical formation were eliminated by treating RAW 264.7 cells with CME‐1. Furthermore, the role of ceramide signalling pathway and anti‐oxidative property were also demonstrated in CME‐1‐mediated inhibition of LPS‐activated primary peritoneal macrophages. In conclusion, CME‐1 suppressed iNOS expression by up‐regulating ceramide‐induced PP2A activation and reducing ROS production in LPS‐stimulated macrophages. CME‐1 is a potential therapeutic agent for treating inflammatory diseases.


Introduction
Inflammation is a defence mechanism triggered by the innate immune system that responds to invasive microbes and tissue injury. In response to pathogen-and environment-derived stimuli, innate immune cells are stimulated to produce pro-inflammatory cytokines, such as tumour necrosis factor-a and interleukins, and generate nitric oxide (NO) from inducible nitric oxide synthase (iNOS) [1,2]. Macrophages are crucial immune cells that are stimulated by receptors that recognize microbial products and elicit inflammatory signalling cascades [3]. Lipopolysaccharide (LPS) is a representative pathogenassociated molecular pattern and a cell wall component of gramnegative bacteria. LPS is considered the most potent immunostimulant among all bacterial cell wall components [4]. Stimulating macrophages with LPS induces various inflammatory signalling cascades by activating toll-like receptor 4 (TLR4) complexes. The interaction recruits proteins including myeloid differentiation primary response gene 88 and interleukin-1 receptor-associated kinases and stimulates tumour necrosis factor receptor-associated factor 6, which subsequently activates nuclear factor (NF)-jB and AP-1 [5]. Additionally, mitogen-activated protein kinases (MAPKs) are central signalling cascades involved in TLR4-activated signalling events [6]. Activating these inflammation-related transcription factors induces the synthesis of pro-inflammatory mediators and the expression of surface molecular proteins, which are involved in cell recruitment and activation [5]. Despite the importance of inflammation in innate immunity, excess inflammatory responses cause pathological conditions such as rheumatoid arthritis and sepsis. Consequently, developing new therapeutic agents for anti-inflammatory therapy is essential for the therapeutic control of inflammatory diseases [7].
Ophiocordyceps is a genus of fungi that grows on the larvae of insects that have been infected by Ophiocordyceps sinensis (O. sinensis) (Fig. 1A). Ophiocordyceps sinensis has been widely used to treat immunological diseases, tumour growth, kidney diseases and inflammatory conditions [8,9]. Ophiocordyceps sinensis mycelium (OM) extract is a promising source of therapeutic agents because it can be purified for mass production. Additionally, the amount of polyphenols and bioactive components is higher in OM than in the fruiting body of O. sinensis [9]. Numerous bioactive compounds, including sterols, cordycepin, polyphenols and polysaccharides, have been found in Ophiocordyceps species. Among these bioactive compounds, polysaccharides are the major antioxidants and have antiinflammatory, anticancer and immunomodulatory effects [10]. CME-1, a novel, water-soluble, 27.6-kD polysaccharide, was purified from OM, and it contained mannose and galactose in a ratio of 4:6 ( Fig. 1B). Wang et al. [11] discovered that CME-1 can protect macrophages by reducing oxidative stress. We recently demonstrated that CME-1 has potent antithrombotic and antitumour properties [12,13].
However, the anti-inflammatory effect of CME-1, a major therapeutic activity of O. sinensis, has not been thoroughly investigated. This study examined the detailed signalling pathway associated with the CME-1-mediated inhibition of iNOS expression in LPS-stimulated macrophages.
Extraction of CME-1 from Ophiocordyceps sinensis mycelia CME-1 was purified as Wang et al. described [11]. Dried OM powder (200 g) was extracted by double-distilled water (DD water) (200 ml) for three times (3 hrs, 25°C). These extracts were collected and then concentrated to obtain a water-soluble fraction of OM (65 g, 33% of crude residues). The OM extraction (2 g) was applied to Sephacryl G-15 column (2.5 9 45 cm) and eluted by DD water to yield CME-1 (12% of OM extraction). CME-1 was determined and collected at the absorbance of 490 nm by sulphuric acid-phenol method. In addition, the CME-1 fraction was hydrolysed in trifluoroacetic acid (8 hrs, 112 ℃). The hydrolysate was eluted through a CarboPac PA10 column (2 9 250 mm) by a mixture of 200 mM NaOH and DD water (the ratio of volume is 8:92). The composition of CME-1 was identified using high-performance anion-exchange chromatography with pulsed amperometric detection (ICS-3000 ion chromatography system; Dionex, Sunnyvale, CA, USA). We next analysed the molecular weight of CME-1 by diffusion-ordered NMR spectroscopy (AV600 NMR spectrometer; Bruker, Rheinstetten, Germany) [14], and the chemical structure was determined by a GCMS profile as described previously [15].
Cell viability assay 2 9 10 5 RAW 264.7 cells per well were seeded with DMEM containing 10% FCS on 24-well culture plates for 24 hrs. The cells were pre-  treated with CME-1 (25, 50 and 100 lg/ml) or an isovolumetric solvent control (PBS) for 20 min. and then stimulated with LPS (1 lg/ml) or left unstimulated for 24 hrs. Cell viability was measured using MTT assay to evaluate the ability of mitochondria in cells [16]. The cell viability index was calculated as follows: (absorbance of treated cells Ä absorbance of control cells) 9 100%.

Determination of nitric oxide production
To determine nitric oxide production, the level of nitrite/nitrate, stable oxidative end products of nitric oxide, was measured as previously described [17] with minor modifications. 8 9 10 5 RAW 264.7 cells were seeded on 6-cm dishes with DMEM containing 10% FCS for 24 hrs. The cells were pre-treated with CME-1 (25, 50 and 100 lg/ml) or PBS for 20 min. and then stimulated with LPS (1 lg/ml) or left unstimulated for 24 hrs. These conditioned media were collected for the analysis. The level of nitrite/nitrate was determined by Griess test (1% sulphanilamide and 0.1% naphthalenediamine dissolved in 2.5% phosphoric acid). The absorbance of samples was determined at 550 nm by a MRX absorbance reader (Dynex Technologies, Chantilly, VA, USA). The concentrations of nitrite/nitrate were calculated by a standard curve performed through the linear regression of absorbance measurements of standard solutions (sodium nitrite dissolved in the same culture medium).

Western blotting assay
Western blotting assay was performed to determine the protein expression in cells as previously described [17]. RAW 264.7 cells (8 9 10 5 cells/dish) were seeded on 6-cm dishes with DMEM containing 10% FCS for 24 hrs. The cells were pre-treated with CME-1 (25, 50 and 100 lg/ml) or PBS for 20 min. and then stimulated with LPS (1 lg/ml) or left unstimulated according to the experimental design. Subsequently, the cellular proteins were extracted with a lysis buffer and prepared with sodium dodecyl sulphate (SDS) loading dye. The prepared protein samples (50 lg) were applied to SDS-polyacrylamide gel for the electrophoresis, and the separated protein bands were then transferred on PVDF membranes (0.45 lm) electrophoretically. The membranes were blocked with 5% skim milk dissolved in TBST buffer (10 mM Tris-base, 100 mM NaCl and 0.01% Tween 20) for 1 hr and then recognized with different primary antibodies before incubated with secondary antibody for 1 hr. The ECL system was used to detect the immune-reactive bands in this study. The densitometry of protein bands was performed by Biolight Windows Application, V2000.01 (Bio-Profil, Vilber Lourmat, France).

Determination of PP2A activity
An immunoprecipitation phosphatase assay kit which manufactured by EMD Millipore (Temecula, CA, USA) was used to measure PP2A activity. Based on the manufacturer's instructions, cellular proteins (200 lg) were immunoprecipitated with an anti-PP2A catalytic subunit antibody, and the immunoprecipitated PP2A was then reacted with the substrate (750 lM phosphoprotein, amino acid sequence KRpTIRR) in a protein phosphatase assay buffer for 10 min. at room temperature. Reactions were terminated by adding a malachite green solution (100 ll). The absorbance was determined by a microplate reader at 650 nm.

Quantification of ceramide species
The quantification of ceramides in macrophages by liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) was performed as described previously [11,17] with some modifications. Briefly, raw 264.7 cells were treated according to the experimental design and then washed twice by ice-cold PBS and collected in 0.5 ml of PBS. The procedure of extraction and quantification of ceramides was performed as previously described [11,17]. In this study, the precursor to product ion transitions were m/z 538.5. Evaluation of intracellular reactive oxygen species (ROS) by flow cytometry RAW 264.7 cells (5 9 10 5 cells/Eppendorf tube) were loaded with 20 lM DCFDA for 20 min. After treatment with CME-1 (100 lg/ml) or PBS for 20 min., cells were then stimulated by the addition of LPS (1 lg/ml) or left unstimulated according to experimental design. The cells were washed with PBS and detached using trypsin. The content of intracellular ROS was evaluated by flow cytometric assay (Beckman Coulter, Brea, CA, USA). The data of each group were collected from 1 9 10 4 cells.

Electron spin resonance (ESR) spectrometry for the measurement of hydroxyl radical formation
The ESR method involved using a Bruker EMX ESR spectrometer (Billerica, MA, USA) as described previously [16] with some modifications. RAW 264.7 cells (5 9 10 5 cells/Eppendorf tube) were pre-treated with CME-1 (100 lg/ml) or PBS for 20 min., and LPS (1 lg/ml) was subsequently added. ESR spectra were recorded by using a quartz flat cell designed for aqueous solutions. The experimental condition was performed by 20 mW of power at 9.78 GHz, with a scan range of 100 G, and the receiver gain was 5 9 10 4 .

Isolation of primary peritoneal macrophages
Male C57BL/6 mice (age, 6 weeks) were utilized to isolate primary peritoneal macrophages as described previously [18] with some modifications. All animal experiments and care procedures conformed to the Guide for the Care and Use of Laboratory Animals (NIH publication no. 85- 23,1996) and were approved by the Institutional Animal Care and Use Committee of Taipei Medical University. Each mouse was injected 2 ml of 4% (w/v) Brewer thioglycollate medium into the peritoneal cavity for three days. The mouse was then killed and injected 5 ml of icecold PBS (contained 3% FCS) into the peritoneal cavity. After injection and gently massage of the peritoneum, the peritoneal macrophages  were collected in tubes. The above procedure was repeated for three times. These collected cell suspensions were centrifuged at 400 g; after discarding the supernatant, the cells were re-suspended in DMEM for the experiments.

Statistical analysis
The results are presented as the mean AE standard error (S.E.M.) and the number of observations (n). First, data were assessed using oneway analysis of variance (one-way ANOVA). If one-way ANOVA revealed significant differences among the group means, a subsequent comparison of Newman-Keuls method was performed. A P value <0.05 was indicated a statistically significant difference.

Results
Effects of CME-1 on nitric oxide production and iNOS expression in RAW 264.7 cells stimulated by LPS Figure 1C illustrates that LPS treatment (1 lg/ml) of RAW 264.7 cells for 24 hrs increased nitric oxide production from 6.0 AE 0.2 to 27.6 AE 0.3 lM (P < 0.001; n = 3). CME-1 treatment (20, 50 and 100 lg/ml) concentration-dependently inhibited nitric oxide production by 34.3%, 50.0% and 68.5%, respectively, in LPS-stimulated RAW 264.7 cells. We then determined whether the expression of iNOS protein, which catalyses nitric oxide generation, is also inhibited by CME-1 in RAW 264.7 cells activated by LPS. Compared with the control group, LPS treatment (1 lg/ml) significantly increased iNOS expression in the treated group, whereas CME-1 treatment (50 and 100 lg/ml) concentration-dependently inhibited iNOS expression in LPS-stimulated RAW 264.7 cells (P < 0.001, n = 3; Fig. 1D). These results suggest that the CME-1-mediated inhibition of nitric oxide formation results from the down-regulation of iNOS expression in RAW 264.7 cells stimulated by LPS. In addition, the cell morphology of RAW 264.7 cells treated with CME-1 (100 lg/ml) in the presence or absence of LPS (1 lg/ml) was observed using microscopy. Unstimulated RAW 264.7 cells exhibited a round morphology, whereas LPS-stimulated RAW 264.7 cells exhibited an irregular morphology, with pseudopodia formation and cell spreading. CME-1 treatment reversed this morphology change in LPS-stimulated RAW 264.7 cells (Fig. 1E).
To examine whether the pharmacological activity or cytotoxicity of CME-1 inhibits nitric oxide production, the viability of CME-1-treated RAW 264.7 cells was determined using a MTT assay. CME-1 treatment (20, 50 and 100 lg/ml) did not exert significant cytotoxic effects on LPS-stimulated RAW 264.7 cells (Fig. 1F).
Inhibition of CME-1 on the NF-jB, Akt and MAPK signalling pathways in RAW 264.7 cells stimulated by LPS To elucidate the mechanism of CME-1-mediated inhibition of iNOS expression in macrophages activated by LPS, we examined the effects of CME-1 on the major pro-inflammatory signal transduction pathways of the innate immune system, including the NF-jB, Akt and MAPK signalling cascades [5,6,19]. We first performed a timecourse analysis of activation of these signalling molecules in LPS-stimulated RAW 264.7 cells. Akt, MAPK and p65 phosphorylation and IjBa degradation peaked at 30 min. after LPS treatment (1 lg/ml) ( Fig. 2A). Therefore, we used this time-point for subsequent experiments. CME-1 treatment (50 and 100 lg/ml) concentration-dependently reversed IjBa degradation and inhibited p65, Akt, extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 phosphorylation in LPS-stimulated RAW 264.7 cells (Fig. 2B-G). Thus, CME-1 treatment comprehensively suppressed these proinflammatory signalling pathways in LPS-stimulated RAW 264.7 cells.

Role of protein phosphatase 2A in the inhibitory effects of CME-1 in RAW 264.7 cells stimulated by LPS
Protein kinase phosphorylation was known to be regulated by protein phosphatases [20]. We examined whether PP2A, a major mammalian protein phosphatase [21], is involved in CME-1-mediated comprehensive inhibition of LPS-stimulated signalling pathways in RAW 264.7 cells. We used OA, a specific PP2A inhibitor [22], to determine the role of PP2A in the inhibitory mechanisms of CME-1. The inhibitory effects of CME-1 on iNOS expression; IjBa degradation; and p65, Akt, ERK, JNK and p38 phosphorylation were all significantly reversed after OA pre-treatment (10 nM) of LPS-stimulated RAW 264.7 cells (Fig. 3A-G). The results indicate a critical role of PP2A in the inhibitory mechanisms of CME-1 in LPS-stimulated RAW 264.7 cells.

Effects of CME-1 on ROS formation in LPSactivated RAW 264.7 cells
Classical radical products such as nitric oxide and superoxide anions, which are generated upon macrophage activation, are Fig. 7 Effects of CME-1 on reactive oxygen species (ROS) and hydroxyl radical production and hypothetical inhibitory mechanism of CME-1-mediated effects (D) in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. (A and B) RAW 264.7 cells (5 9 10 5 cells/Eppendorf tube) were treated with or without CME-1 (100 lg/ml) for 20 min. followed by LPS (1 lg/ml) for the indicated periods to trigger ROS formation. Intracellular ROS content was determined using a DCFDA assay as described in the Methods. Data are presented as the mean AE S.E.M. (n = 3). *P < 0.05 and **P < 0.01, compared with the control group; # P < 0.05, compared with the LPS group. (C) RAW 264.7 cells (5 9 10 5 cells/Eppendorf tube) were treated with PBS (trace a and b) or CME-1 (trace c and d, 100 lg/ml) and then treated with or without LPS (1 lg/ ml). Asterisks indicate the formation of hydroxyl radicals. Spectra are representative examples of three similar experiments. associated with cell and tissue damage and redox signalling [24]. To evaluate the efficacy of CME-1 in reducing ROS formation in LPS-activated macrophages, DCFDA, a cell-permeative ROS-sensitive dye, was used [16]. Figure 7A illustrates that treatment with LPS (1 lg/ml) for 60 min. stimulated ROS generation significantly (2.3 AE 0.3-fold, P < 0.01, n = 3) in macrophages compared with that of the control group. LPS-stimulated ROS production in macrophages was reduced by the administration of CME-1 (100 lg/ml) to 94.4% (Fig. 7B). Moreover, a typical electron spin resonance (ESR) spectrometry signal of hydroxyl radical formation was observed in LPS-stimulated (1 lg/ml) cells compared with resting (phosphate-buffered saline (PBS)-treated) cells (Fig. 7C,  traces a and b). CME-1 (100 lg/ml) significantly attenuated hydroxyl radical formation in RAW 264.7 cells stimulated by LPS (1 lg/ ml) (Fig. 7C, trace c).
Ceramide signalling pathway and anti-oxidative property expressed in the inhibition of CME-1 on LPS-activated primary peritoneal macrophages In addition, we further determined the inhibitory effects of CME-1 in primary peritoneal macrophages stimulated by LPS. As shown in Figure 8A and B, CME-1 (100 lg/ml) significantly reduced nitric oxide production as well as iNOS expression in LPS (1 lg/ml)-activated peritoneal macrophages. LPS (1 lg/ml)-stimulated irregular morphology with pseudopodia formation of peritoneal macrophages was abolished by the addition of CME-1 (100 lg/ml) (Fig. 8C). Moreover, the pre-treatment of 3-OMe-SM (30 lM) significantly reversed CME-1 (100 lg/ml) suppressed nitric oxide production, iNOS expression, morphological change and the phosphorylation of ERK and Akt in peritoneal macrophages stimulated by LPS (1 lg/ml) (Fig. 8A-D). On the other hand, in primary peritoneal macrophages, CME-1 (100 lg/ ml) also revealed potent anti-oxidative property against LPS-induced ROS formation (Fig. 8E).

Discussion
In Asia, Ophiocordyceps species are widely used in herbal medicines to treat respiratory, hepatic, kidney and inflammatory diseases. Polysaccharides extracted from Ophiocordyceps species possess immunoregulatory, antitumour and anti-inflammatory properties [8,9]. Wang et al. [11] isolated CME-1, a novel water-soluble polysaccharide, from Ophiocordyceps sinensis mycelia. CME-1 has been demonstrated to have anti-ROS, antitumour and antithrombotic activities [11][12][13]. Here, we demonstrated that CME-1 has a potent inhibitory effect on nitrite formation and iNOS expression in LPS-stimulated RAW 264.7 cells and primary peritoneal macrophages. As essential factors in inflammatory responses, iNOS and subsequent excess nitric oxide production are associated with the pathologies of numerous inflammatory diseases [25]. The marked effect of CME-1 on iNOS suppression indicates that CME-1 is a potential therapeutic agent for inflammatory diseases. CME-1 also did not exhibit cytotoxicity towards CME-1-treated macrophages. In addition, Wang et al. [11] indicated that CME-1 has a cytoprotective effect against oxidative stress in hydrogen peroxide-treated macrophages. Because macrophages are indispensable in immune responses, these results may also imply that CME-1 exhibits immunomodulatory activity.
The acute inflammatory response of macrophages is an essential part of the host defence and innate immunity. Macrophage activation is stimulated by receptors that recognise microbial components, which subsequently activate inflammatory signalling cascades [3]. Stimulating macrophages with LPS, the most potent immunostimulant of all bacterial cell wall components, elicits various signalling events through TLR4 activation for macrophage effector functions [4]. Numerous studies have indicated that the activation of NF-jB, MAPK and PI3K/Akt signalling pathways plays crucial roles in TLR4-activated macrophages and gene expression [5,6,19]. We determined the effects of CME-1 on IjBa degradation and p65, Akt and MAPK phosphorylation in LPS-stimulated RAW 264.7 cells. CME-1 treatment generally suppressed IjBa degradation and protein kinase phosphorylation in LPS-stimulated RAW 264.7 cells. Protein phosphorylation is a reversible process that is balanced by protein kinases and phosphatases [20]. We thus determined whether protein phosphatase regulation causes the CME-1-induced comprehensive abolishment of protein kinase phosphorylation.
PP2A serves a leading proportion of mammalian phosphatases in cells, and it constitutes up to 80% of serine and threonine (Ser/Thr) protein phosphatases. This principal class of Ser/Thr protein phosphatases plays critical roles in modulating development, cell death and various signalling pathways [26]. Additionally, PP2A modulates IjBa degradation and p65, Akt and MAPK phosphorylation [27][28][29]. Therefore, we postulated that PP2A is involved in the inhibitory effects of CME-1 on these pro-inflammatory signalling pathways. OA is a representative diarrhoeic shellfish poisoning toxin and potent PP2A inhibitor [22]. In the present study, OA pre-treatment significantly reversed CME-1-suppressed iNOS expression; IjBa degradation; and p65, Akt and MAPK phosphorylation in LPS-stimulated RAW 264.7 cells. These data imply that PP2A may be an essential part of the inhibitory mechanisms of CME-1 in stimulated macrophages. To further determine the effect of CME-1 on PP2A in macrophages, we examined PP2A activity using an immunoprecipitation phosphatase assay kit. In addition, the reversible methylation of Leu309 in a conserved TPDYFL motif of the carboxyl-terminus of PP2Ac was known to regulate phosphatase activity and holoenzyme assembly [26]. We thus evaluated dimethyl-PP2A expression in CME-1-treated RAW 264.7 cells. CME-1 treatment upregulated PP2A activity and dimethyl-PP2A expression in RAW 264.7 cells, and OA preincubation significantly reversed CME-1enhanced PP2A activation.
Three major families of endogenous molecules regulate PP2A activity, namely polyamines, metal cations and ceramides [30]. Ceramides are a class of sphingolipid metabolites and have been reported to play a critical role in regulating immunity and inflammation [31]. PP2A is a primary target for ceramide regulation. A recent study indicated that ceramide directly binds to SET, an inhibitory protein of PP2A, relieving its inhibitory action and thus increasing PP2A activity [32]. According to knowledge gained in this emerging field, FTY720, a sphingosine analogue, was developed as an immunosuppressive agent and was also found to initiate PP2A activation [33]. In the present study, pre-treatment with 3-OMe-SM significantly abolished CME-1-induced PP2A activation and suppression of iNOS expression; IjBa degradation; and p65, Akt and MAPK phosphorylation in RAW 264.7 cells and primary peritoneal macrophages stimulated by LPS. Furthermore, CME-1 significantly increased ceramide formation in LPS-activated macrophages. These data elucidate a critical role of ceramide-activated PP2A signalling in the inhibitory mechanisms of CME-1 in acute inflammation. However, Wang et al. [11] indicated that the pre-treatment of CME-1 revealed cytoprotective effect on macrophages through the inhibition of H 2 O 2 -induced tremendous ceramide formation. In the present study, ceramide increased within short-term treatment of CME-1 in LPS-activated macrophages. On the other hand, in the study of Wang et al. [11], the significant inhibition of ceramide formation by CME-1 occurred in macrophages treated with H 2 O 2 for 6 hrs. These results may imply that CME-1 has distinct activity on ceramide formation in different pathological conditions.
Oxidative stress is a harmful consequence of inflammation because irreversible oxidative cell or tissue damage may be associated with various diseases [24]. The term 'oxidative stress' has been defined as an imbalance in the pro-oxidant and anti-oxidant systems. Pro-oxidants, including superoxide anions; hydrogen peroxide; hydroxyl, alkoxy and peroxy radicals; and peroxynitrite, are generally considered ROS [34]. Upon pathogen recognition, macrophages produce ROS through NADPH oxidase (NOX) activation. This oxidative burst may be involved in cell and tissue damage, pathogen killing and inflammatory signalling [35]. Furthermore, up-regulation of anti-oxidant enzymes was found to suppress nitric oxide production or NF-jB activation in macrophages [24]. NOX-dependent ROS production was associated with the stimulation of NF-jB and p38 signalling, which is required for LPS-induced activator protein 1-driven transcription [36]. In the present study, we determined the effects of CME-1 on ROS formation in LPS-stimulated RAW 264.7 cells and primary peritoneal macrophages using a DCFDA assay and ESR spectrometry. Treatment with CME-1 significantly abolished LPS-induced ROS production in macrophages. These results indicate that treatment with CME-1 can relieve inflammatory diseases by reducing oxidative stress and its related inflammatory signalling.
Uncontrolled inflammation leads to various pathological conditions such as rheumatoid arthritis and sepsis [7]. Developing new anti-inflammatory treatments is therefore necessary for improving therapy for inflammatory diseases. Our findings demonstrate that CME-1 significantly reduced iNOS expression in LPS-activated macrophages by up-regulating the ceramide-PP2A signalling pathway and suppressing ROS formation (Fig. 7D). In conclusion, CME-1 is a potential therapeutic agent for treating and preventing inflammatory diseases.